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Purpose/Objective(s): American Indians (AIs) present with more advanced stages of cancer 
and, therefore, suffer from higher cancer mortality rates compared to non-AIs. Under the 
National Cancer Institute (NCI) Cancer Disparities Research Partnership (CDRP) Program, we 
have been researching methods of improving cancer treatment and outcomes since 2002, 
for AIs in Western South Dakota, through the Walking Forward (WF) Program. Materials/
Methods: This program consists of (a) a culturally tailored patient navigation program that 
facilitated access to innovative clinical trials in conjunction with a comprehensive educational 
program encouraging screening and early detection, (b), surveys to evaluate barriers to access, 
(c) clinical trials focusing on reducing treatment length to facilitate enhanced participation using 
brachytherapy and intensity modulated radiotherapy (IMRT) for breast and prostate cancer, 
as AIs live a median of 140 miles from the cancer center, and (d) a molecular study (ataxia 
telangiectasia mutated) to address whether there is a specific profile that increases toxicity risks. 
Results: We describe the design and implementation of this program, summary of previously 
published results, and ongoing research to influence stage at presentation. Some of the critical 
outcomes include the successful implementation of a community-based research program, 
development of trust within tribal communities, identification of barriers, analysis of nearly 
400 navigated cancer patients, clinical trial accrual rate of 10%, and total enrollment of nearly 
2,500 AIs on WF research studies. Conclusion: This NCI funded pilot program has achieved 
some initial measures of success. A research infrastructure has been created in a community 
setting to address new research questions and interventions. Efforts underway to promote 
cancer education and screening are presented, as well as applications of the lessons learned 
to other health disparity populations – both nationally and internationally.
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(Petereit et al., 2004; Rogers and Petereit, 2005). In 2003, a review 
of the Rapid City Regional Hospital (RCRH; Rapid City, South 
Dakota) tumor registry (1990–2000) revealed that 50% of AI 
cancer patients presented with stage III–IV breast, colorectal, 
prostate, cervical, and lung cancer compared with 36% of non-
American Indians presenting with advanced stage disease for 
those malignancies (Petereit et al., 2004). In the same region 
there are non-AI cancer patients who are medically underserved 
as well – many who live in remote rural locations. Root causes for 
these disparities are multiple, and there is a growing literature 
dedicated to examining and solving the patient-, physician-, and 
health-care system related factors that contribute to inequities 
in health outcomes by race and ethnicity (Lannin et al., 1998; 
Geiger, 2003).
AI populations have valid reasons for distrust of researchers 
(Burhansstipanov et al., 2009). Christopher et al. (2005) docu-
mented multiple examples of Natives’ distrust of researchers based 
on numerous historical events. Unethical research or care  protocols 
INTRODUCTION
In the most recent report (2009) to the nation on the status of 
cancer by the Centers for Disease Control (CDC), cancer mortal-
ity rates declined for all racial and ethnic groups, except American 
Indians (AI) and Alaskan Natives for whom cancer death rate trends 
remained level. Unfortunately, these groups did not experience the 
same annual 1.6% decrease in mortality from 1999 to 2006 (Espey 
et al., 2007). AIs who live in the Northern Plains (NP) suffer age-
adjusted mortality rates that are significantly higher than those for 
whites for cancers for which an effective screening test exists. The 
NP encompass a large geographic swath from Indiana to Montana 
and includes the Dakotas where a majority of Lakota Sioux live 
(Figure 1). The cancer-specific mortality rates for NP AIs are 79% 
higher for cervical cancer, 58% higher for colorectal cancer, and 
49% higher for prostate cancer (Espey et al., 2003).
AIs utilize cancer screening at much lower rates compared 
to the national average (Ward et al., 2004). As a result, NP AIs 
present with disparately high rates of advanced-stage cancer Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 11  |  2
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Patient Navigation (PN) has emerged as a new strategy to 
address cancer disparities, and in our region to address issues of 
medical mistrust. In the early 1990’s Freeman and colleagues in 
Harlem demonstrated improved 5-year survival from 39 to 70% 
for breast cancer patients that underwent their model of patient 
navigation (Freeman et al., 1995; Freeman, 2006). As part of the 
NCIs CDRP program, each site was to implement PN tailored to 
their respective population.
Clinical trial participation is critical as it provides patients access 
to state-of-the-art therapy; safe and effective treatments that are 
closely monitored; and the potential for improved clinical out-
comes, including quality of life. The rate of accrual in clinical trials 
among minority, rural, and lower socioeconomic subpopulations 
is low in the US and is approximately 1% (Maurer et al., 2001; 
Sateren et al., 2002; Murthy et al., 2004). This may be a result of 
numerous barriers to accessing health care that could potentially 
exacerbate known cancer-related health disparities among under-
served populations. (Shavers and Brown, 2002; Petereit et al., 2004; 
Espey et al., 2007) The low participation rates among minorities 
also limit the treatment implications of data derived from clinical 
trials. As part of the NCI CDRP initiative, clinical trial development 
tailored to these special populations, and potential enrollment, was 
a critical outcome.
While the emphasis of this article is on the WF program, we 
will also describe how the “lessons learned” in this population may 
be applied to other disparate populations in the US and abroad.
MATERIALS AND METHODS
PRIMARY HYPOTHESIS
AIs in western, SD, live a median of 140 miles from the cancer 
center in Rapid City (Figure 1). The identification of barriers which 
prevent AIs from presenting with earlier stages of cancer, or in some 
circumstances not at all, was investigated. It was hypothesized that 
have historical relevance to government policies designed to anni-
hilate AIs in the nineteenth and the first half of the twentieth 
centuries; others are more recent and include sterilization of AI 
women without informed consent in the 1970s (Burhansstipanov 
et al., 2009). Most recently, Arizona State University (ASU) agreed 
to pay $700,000 to 41 members of the Havasupais Indian tribe 
to settle legal claims that university researchers improperly used 
tribe members’ blood samples in genetic research (Mello and Wolf, 
2010). Although the initial tragedy of Wounded Knee (Pine Ridge, 
SD) occurred over 100 years ago (1890), when honoring those 
who died in 1990, racist violent attacks were again made against 
the Natives in this region. Thus, these and many other histori-
cal trauma events are fresh in the memory of AIs living in SD. 
Appreciating and understanding the multiple reasons for this lack 
of trust is critical in order for researchers to pursue areas of inves-
tigation in this population (Petereit and Burhansstipanov, 2008; 
Burhansstipanov et al., 2009).
The National Cancer Institute (NCI) created the Cancer 
Disparities Research Partnership (CDRP) pilot program in 2002 
to reduce cancer disparities observed among underserved sections 
of the United States population. RCRH was one of six sites to receive 
the grant. RCRH provides secondary and tertiary cancer care for 
approximately 60,000 adult AIs living in nearby reservations, sur-
rounding rural communities, and Rapid City itself. The three res-
ervations served include Pine Ridge, Rosebud, and Cheyenne River 
(Figure 1). The geographic area is approximately 100,000 square 
kilometers. The 1n order to address the ominously high-cancer 
death rates for NP AIs, a multifaceted program called Walking 
Forward (WF) was developed through NIH funding (PI Petereit D). 
The Cancer Care Institute (CCI) is located within RCRH which is 
the central location for WF. This program will be further described 
and includes assessment of cancer barriers, clinical trials, radiog-
enomics, and patient navigation.
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the research studies were conducted within the community. Many 
tribal members and leaders were rightfully suspect that our project 
would be another “fly by night” operation where we would come in, 
abstract the data, leave, and publish the results without any feedback 
or continuity (a phenomenon commonly referred to as “helicopter 
research” by many Native communities). Thus, quarterly reports 
were presented to the tribal councils so they could monitor ongoing 
research – both at the community level and at the cancer center.
IRB APPROVAL
The three reservations in western, SD, are considered sovereign 
nations which mandate a more comprehensive IRB approval pro-
cess. IRB approval was required from the Aberdeen Area IHS (IHS 
IRB of record for the NP), National IHS, RCRH, the University of 
Wisconsin (UW), the Mayo Clinic (ataxia telangiectasia mutated, 
ATM study only) and the NCI. The Aberdeen Area IHS IRB would 
consider protocols only after the scientific validity was reviewed 
and approved by the UW IRB, and only after letters of support 
and/or tribal resolutions were obtained from the service unit direc-
tor of IHS, tribal councils from each reservation, as well as a let-
ter of support from the Aberdeen Area Tribal Chairmens’ Health 
Board (AATCHB). Therefore, each protocol required seven letters 
of support and/or resolutions. With 9 initial protocols 72 letters 
of support were received. Due to the rigorous and necessary peer-
review process for our project, it took a minimum of 12 months to 
activate the first study (Table 1). Consents were written in a cultur-
ally appropriate manner with guidance, direct feedback and input 
from the AI community, often through focus groups. This process 
a major barrier to obtaining timely and effective cancer treatment 
was distance from the cancer center as conventional radiotherapy 
requires 6–8 weeks. Therefore, phase II studies were developed to 
address this potential barrier for malignancies commonly seen 
among the AIs, breast cancer and prostate cancer, utilizing inten-
sity modulated radiotherapy (IMRT) and brachytherapy. At the 
community level, we engaged in several social science studies to 
determine potential barriers to cancer screening and early detec-
tion. In addition, our community staff was responsible for outreach, 
education, and networking.
COMMUNITY-BASED PARTICIPATORY RESEARCH
In 2001, the NCI released a Request for Application (RFA) request-
ing planning grant applications from communities that experience 
health disparities (Table 1). The PI coordinated meetings with both 
the tribal leadership and Indian Health Service (IHS) to introduce 
the general principles of cancer treatment and cancer research stud-
ies and to present the RFA for their consideration. The sentinel 
issues raised were trust and levels of commitment from physicians 
and researchers, high-cancer death rates, and potential resolutions. 
After much discussion, the tribal councils approached were in favor 
of partnering with RCRH on the research proposal. They prepared 
and passed a tribal resolution in support of the study and included 
letters of support (Petereit and Burhansstipanov, 2008).
Once the grant was rewarded in 2002, the PI returned to each 
reservation for further discussion and implementation. Since the 
tribal councils are elected every other year, it was critical to maintain 
a constant level of dialog for ongoing approval for WF as many of 
Table 1 | Walking forward timeline.
Date Activity
Spring 2000 PI initiates dialog with tribal councils to present the current status of cancer treatment in Rapid City
July 2001 RFA issued
Sept 2001 Meetings with tribal councils to discuss RFA
Oct 2001 Grant preparation
March 2002 Grant submitted
Sept 2002 Grant awarded to Rapid City
Sept 2002 – May 2003 Staff hiring, protocol development
January 2003 Quarterly meetings with tribal councils to discuss implementation of walking forward
February 2003 – April 2003 Presentations to multiple tribal councils, tribal health boards, IHS clinics to obtain letters of support for each protocol
June 2003 First protocol submitted to one 4 IRBs (Patient Navigation Study)
January 2004 Patient navigation protocol activated
October 2004 All 12 protocols activated
Sept 2007 Supplemental funding through NCI to promote cancer screening through community education
May 2008 Partnership with Native American Cancer Research Inc. on a project funded by the National Center on Minority Health and 
Health Disparities to promote cancer education
September 2008 Over 1,800 American Indians enrolled on various WF clinical research trials
December 2008 Rapid City submits competing renewal application to NCI for continuation of WF program
September 2009 Rapid City receives funding for another 5 years
January 2011 Nearly 2,500 American Indians enrolled on various WF clinical research trials
April 2010 Small award from Potowatami Tribe to promote cancer screening in the community
March 2011 Comprehensive patient navigation implemented with WF staff embedded within each IHS hospital to facilitate cancer 
screening
November 2011 Partnership with South Dakota Department of Health, on a project funded by the CDC, to expand and support existing patient 
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utilizing IMRT and brachytherapy with the theme of   reducing 
overall treatment time. Eligible stage I breast cancer patients were 
offered breast brachytherapy; whereas, prostate patients were 
offered IMRT ±  brachytherapy depending upon their risk strati-
fication as defined by D’Amico et al. (1998). Details of these phase 
II trials have previously been described (Petereit et al., 2004; Ritter 
et al., 2009; Adkison et al., 2010).
SUMMARY OF M AND M
Through patient education, screening, assessing potential barriers 
to health care, and enrollment on innovative treatment strategies, it 
was hypothesized that AIs would eventually present earlier in their 
disease process, have increased access to NCI sponsored clinical tri-
als, and ultimately experience higher cure rates. In addition, clinical 
trials were developed to meet the needs of the population served. 




Between February 2004 and September 2009, 332 AI cancer patients 
received PN services throughout cancer treatment. The median 
number of contacts with a navigator was 12 (range, 1–119). The 
median time spent with the navigator at first contact was 40 min 
(range 10–250 min.) and 15 min for subsequent contacts. Patients 
treated with radiation therapy with curative intent who underwent 
PN had fewer days of treatment interruption (mean, 1.7 days; 95% 
CI, 1.1–2.2 days) than historical controls who did not receive PN ser-
vices (mean, 4.9 days; 95% CI, 2.9–6.9 days; Guadagnolo et al., 2011).
COMMUNITY SURVEY
Given that most of the AI communities reside in rural locations, 
distance and transportation present significant barriers to access-
ing health care as 47% of the respondents identified lack of trans-
portation as one of the most common barriers to accessing care. 
For example, 75% of respondents reported traveling more than 50 
miles for tertiary medical care while AIs seeking cancer treatment 
at RCRH traveled an average of 140 miles one way (Guadagnolo 
et al., 2009b; Pandhi et al., 2010b).
The respondents also identified lack of satisfaction in inter-
actions with medical providers and a lack of confidence in their 
abilities as additional barriers to care. AI cancer patients exhibited 
a significantly higher mistrust (p = 0.0001) and lower satisfaction 
(p = 0.0001) with health care than whites (Guadagnolo et al., 2008).
Additional barriers specific to accessing cancer-related health 
care, including cancer screening were also identified. Overall, only 
43% of participants reported ever having had any cancer screening 
tests. Analysis of cancer-specific screening rates showed the fol-
lowing percentages: cervical 48% (n = 596), breast 59% (n = 369), 
prostate 34% (n = 115), and colorectal 20% (n = 56). These rates 
are significantly lower than the published rates for not only US non-
Hispanic Whites, but also for AI, specifically the NP AI population 
(Espey et al., 2007; Pandhi et al., 2010b). There were several sig-
nificant determinants of cancer screening prevalence. Most impor-
tantly, those who reported that a doctor or nurse had recommended 
cancer screening had nearly 12 times the odds of ever receiving 
screening (OR 11.99; 95% CI 7.35–19.56; Pandhi et al., 2010b).
has been described in further detail. (Molloy et al., 2007; Petereit 
et al., 2008) The IRB of record for WF was RCRH, particularly for 
all research activities that took place at the cancer center in Rapid 
City. Finally, all manuscripts were reviewed and edited for potential 
approval by the IHS and RCRH IRBs.
ATAxIA TELANgIECTASIA MUTATED
It was the subjective experience of CCI radiation oncologists that 
AIs experience higher rates of radiation toxicities that could repre-
sent a treatment barrier as well. A genetic milieu may exist which 
renders AIs more sensitize to radiation. Therefore, a laboratory 
study was conducted to determine whether AIs have a higher ATM 
variant rate compared to non-AIs. The ATM gene was analyzed 
from both AI and non-AI patients undergoing radiation with pro-
spective scoring of toxicities. The methodology has been previously 
described (Petereit and Burhansstipanov, 2008; Petereit et al., 2010).
PATIENT NAVIgATION
A process map for patient navigation was developed to overcome 
the identified barriers and build trust within the community. 
Although this model shared similar characteristics to the one 
developed by Feeman (2004–2006), previous director of the NCI 
Center to Reduce Cancer Health Disparities, our model was tai-
lored to meet the needs of our population. Our program has been 
previously published and detailed elsewhere (Petereit et al., 2008; 
Guadagnolo et al., 2011).
The WF patient navigation program included services for cancer 
patients and a community outreach program. Cancer patients were 
assisted by hospital based patient navigators to address barriers and 
facilitate cancer-related care, encourage clinical trial participation, 
and follow-up assessment. The community research representatives 
(CRR), based in their respective communities on each of the three 
reservations, facilitated an education and outreach component. All 
of the CRRs were AI and members of the respective tribe they served. 
These CRRs promoted early detection through screening and raised 
awareness of the clinical trials by implementing culturally relevant 
education modules. They also administered a survey to determine 
the barriers and determinants of cancer screening. A core feature 
of the navigation program was ensuring cultural competency of the 
navigators as detailed in a previous publication (Molloy et al., 2007).
IDENTIFYINg BARRIERS TO HEALTH CARE (SURVEYS)
To identify the barriers to timely cancer diagnosis and treatment, 
a community survey and a cancer patient survey were developed 
through a collaborative process employing a community-based par-
ticipatory research (CBPR) methodology. The community survey 
was implemented among nearly 1,000 AI in the target communities, 
while the cancer patient survey was implemented prospectively 
among 165 newly diagnosed cancer patients at RCRH’s CCI, of 
which 52 were AI. The methodologies and results have been previ-
ously published (Guadagnolo et al., 2009a,b; Pandhi et al., 2010a,b).
CLINICAL TRIALS
Clinical trial enrollment data was prospectively tracked for all navi-
gated AI patients. Enrollment of AIs on NCI sponsored clinical trials 
was a high priority as approximately 75 studies were open. Phase II 
clinical trials were available for prostate and breast cancer patients www.frontiersin.org  June 2011  | Volume 1  |  Article 11  |  5
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correlating SNP data to clinical toxicities to assess a potential rela-
tionship. While there were initial concerns that this study could not 
be opened, or accrued to, due to concerns of genetic testing in a 
disparate population, IRB approval was rapidly obtained with only 
a few patients refusing participation. Patients were eager to enroll as 
they believed it could help the next generation of cancer patients.
NCI SPONSORED CLINICAL TRIALS
During the WF era (2002-present), 358 patients were enrolled on 
NCI studies, including 32 AIs. When these numbers are combined 
with the above investigator initiated trials, the total number of 
patients accrued was 619, of which 145 were AI. We have enrolled 
nearly 2,500 AIs on various WF research studies. While the majority 
of enrolled participants were on social science investigations, these 
studies all required IRB approval, individual informed consents, 
and in essence, validated the trust that was established within each 
community / reservation.
REASONS FOR LACK OF ACCRUAL
Between September 2006 and January 2008, 891 new cancer patients 
(AI and non-AI) were evaluated for potential participation in a 
clinical trial. Seventy-eight patients (9%; 95% CI, 7–11%) were 
enrolled on a clinical treatment trial. For 73% (95% CI, 69–75%) 
of patients (646 of 891) lack of relevant protocol availability or 
protocol inclusion criteria restrictiveness was the reason for 
non-enrollment. Only 45 (5%; 95% CI, 4–7%) patients refused 
enrollment on a trial. Of the 78 enrolled on a trial, 6 (8%; 95% CI, 
3–16%) were AI. Further details of this analysis have been published 
(Guadagnolo et al., 2009c).
DISCUSSION
Walking Forward is a multifaceted cancer disparity program that 
has achieved some initial level of success including establishment 
of trust within the AI community, development of research infra-
structure in a community hospital, high enrollment of AIs on 
various research protocols, implementation of advanced radiation 
technologies, and the creation of a comprehensive patient naviga-
tion program. The process of initiating, nurturing and establish-
ing a trusting partnership with any underserved community must 
occur at multiple levels, beginning with shared participation in 
the planning processes, continued consultation through project 
implementation, and sharing responsibilities for data analyses and 
writing and dissemination of study findings. Establishing a trusting 
partnership with the community takes time and is the foundation 
of CBPR, particularly with the AI population where historic trauma 
and distrust of researchers is pervasive. Our patient navigation 
program was key to establishing trust at the community level which 
enhanced cancer care and clinical trial enrollment at the cancer 
center in Rapid City as detailed in Table 1.
Patient navigation is a health access barrier-focused intervention 
becoming increasingly adopted as a health care delivery innovation 
to address disparate cancer-related health outcomes. Such dispari-
ties are well-documented among minority and low income patients 
who often face multiple health access barriers ranging from finan-
cial and logistical constraints in obtaining health care to cultural 
and trust issues that impede health care provision (Guadagnolo 
et al., 2011).
CANCER SURVEY
There was a significant difference in mean scale scores for medical 
mistrust by race. In the univariate analysis, AIs exhibited higher 
mean scores for mistrust than Whites (p = 0.0001). A multivariable 
regression model including race, age, gender, employment status, 
annual income, education level, and distance from CCI revealed 
that AIs exhibited a significantly higher level of mistrust (p = 0.008), 
even when adjusting for the other variables. No other variable was 
associated with a significant difference in mistrust scores in the 
multivariable model (Guadagnolo et al., 2009a).
There was also a significant difference in mean scale scores by 
race for satisfaction with the health care system and providers. 
AI patients had lower mean scale scores for satisfaction than did 
White patients (p = 0.0001). In a multivariable model analyzing 
satisfaction mean scale score showed that AIs had significantly lower 
scores for satisfaction with health care than Whites (p = 0.0001), 
even after adjusting for age, gender, employment status, income, 
education level, and distance from CCI (Guadagnolo et al., 2009a).
CANCER EDUCATIONAL WORKSHOPS AND SCREENINg
In the last 3 years, cancer education efforts were initiated with the 
goal of increasing screening rates by 20%. Cancer screening educa-
tional workshops were conducted as an educational intervention. A 
total of 410 individuals participated in cancer screening workshops. 
Participants demonstrated significant increases in cancer screening-
related knowledge levels with an increase in knowledge quiz score of 
21% in cervical cancer workshops (p < 0.001), 24% in breast cancer 
workshops (p < 0.001), 21% in prostate cancer workshops (p < 0.001), 
and 22% in colorectal cancer workshops (p < 0.001). We are currently 
following up on all participants eligible for cancer screening to deter-
mine any increase in the screening rates post-workshop. To date we 
have followed up on 125 participants eligible for screening and prelimi-
nary data indicates an increase of screening rate for breast, cervical, and 
prostate cancer, but not colorectal cancer (Subrahmanian et al., 2011).
PHASE II CLINICAL TRIALS
Forty-two non-AI and 5 AI patients have been enrolled on the 
breast brachytherapy study with ongoing accrual. The low-risk 
IMRT hypofractionated prostate study has enrolled 307 patients 
among 5 institutions nationally, with 43 enrolled from Rapid City 
(4 AIs). Preliminary results have been published with excellent bio-
chemical control and acceptable toxicities (Ritter et al., 2009). This 
study continues to accrue patients, and is one of the most successful 
trials ever opened in Rapid City in regards to treatment tolerance, 
patient satisfaction, and accrual. Eight patents (1 AI) have enrolled 
on our intermediate-risk study investigating a short course of IMRT 
followed by a permanent seed implant boost, and 53 patients (1 AI) 
have been enrolled on the high-risk prostate study, in conjunction 
with UW, which investigates hypofractionated radiation to both 
the prostate and pelvic lymph nodes. Preliminary results from the 
high-risk study were recently published (Adkison et al., 2010).
ATAxIA TELANgIECTASIA MUTATED
We recently reported preliminary ATM sequencing data for 100 AI 
and 100 non-AI patients (Petereit et al., 2010). There were no sta-
tistically significant differences for total prevalence of SNPs among 
AI (40%) and non-AI (48%) patients (p = 0.32). We are currently Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 11  |  6
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Komen Foundation, the American Cancer Society, a CDC funded 
colorectal project, the regional radiologists and other groups that 
perform cancer screening. Through these expanded screening inter-
ventions, it is the long-term goal of WF to lower cancer mortal-
ity rates by influencing stage at presentation, as well as increasing 
clinical trial accrual.
CLINICAL TRIALS
Clinical trial enrollment is the cornerstone of advancing cancer 
care. Although many clinical trials were available through the 
cooperative group mechanism, many of these studies had eligibility 
criteria that were too restrictive, or did not meet the needs of our 
population. Therefore, clinical trials were developed for common 
cancers observed in the AI and non-AI population that addressed 
their unique needs.
A 1992–1993 Medicare survey reported that only 1.4% of 
Medicare patients underwent breast conservation in Rapid City, 
SD (Wennberg, 1996; Kanekar and Petereit, 2009). Although 
the reasons are many, the distance from the cancer center is 
presumed to be a major impediment to breast conservation. The 
inverse relationship between breast conservation rates and the 
distance from the cancer center is supported by the observation 
of lower rates of breast preservation in rural areas (Nattinger 
et al., 1992; Wennberg, 1996). Therefore, our phase II breast 
brachytherapy protocol was activated to address the unique 
needs of our patients. To date, no patients have locally recurred 
and cosmetic outcomes have been good to excellent with follow-
up and further enrollment continuing. Breast brachytherapy 
has expanded the options for breast preservation for patients 
in western, SD, as many patients live 2–3 h from the cancer 
center in Rapid City.
The incidence of prostate cancer for AI men parallels the 
incidence of US men as the most common malignancy. Three 
phase II clinical trials were implemented for men with low-, 
Patient Navigation was one of our key strategies to address com-
plex patient issues among the AIs. Much of the PN literature address-
ing care of cancer patients focuses on increasing screening incidence 
and/or decreasing intervals between screening and diagnostic man-
agement of initiation of treatment for various cancers (Weinrich 
et al., 1998; Dignan et al., 2005; Nash et al., 2006; Christie et al., 
2008; Wells et al., 2008), and most studies do show improvement in 
the corresponding outcomes when PN is available. AIs specifically 
have been shown to benefit from PN in the setting of facilitating 
screening and timely diagnostic follow-up (Burhansstipanov et al., 
2000; Dignan et al., 2005). However, few studies report upon the 
role of PN after a patient is diagnosed and undergoing the rigors 
of cancer treatment (Dohan and Schrag, 2005; Wells et al., 2008), 
arguably a time when patients may experience more barriers due 
to logistical complexities and financial burden of receiving many 
weeks or months of treatment, e.g., RT or chemotherapy.
Our finding of fewer treatment interruptions for patients 
undergoing curative RT is one that has important implications 
for this population that has been shown to have disparately high-
cancer mortality. (Rades et al., 2008; McCloskey et al., 2009) This 
is especially relevant for treatment of cervical cancer – a disease 
that disproportionately affects poor and minority women, and 
for which AI women in the NP have the highest incidence and 
mortality (Petereit et al., 1995; Espey et al., 2007; Haverkamp et al., 
2008). Patient navigation, in our program, seemed to offer an 
effective strategy to mitigate barriers that may prolong definitive 
cancer treatment.
Multiple studies have indicated that clinical trial participation 
among AI cancer patients is low with trial accrual rates of <1% 
(Sateren et al., 2002; Murthy et al., 2004; Stewart et al., 2007). 
Reasons underpinning low minority participation in clinical trials 
are multi-factorial and may differ across regions as well as between 
racial/ethnic groups (Bruner et al., 2006; Ford et al., 2008). In this 
region, it has previously been shown that AI cancer patients exhibit 
relatively high rates of medical mistrust and dissatisfaction with 
prior health care received (Guadagnolo et al., 2009a). Our PN pro-
gram specifically targets health access barriers in this population 
and seeks to address them in a culturally sensitive manner while 
partnering with tribal communities. This effort toward establishing 
rapport with AI patients and communities to meet their needs may 
account for our relatively higher proportion of AI patients willing 
to enroll on clinical trials.
A primary reason for clinical trial ineligibility is advanced stage/
metastasis at presentation. To address this stage disparity, we have 
embarked upon community education to enhance cancer awareness 
for screen detectable cancers on all three reservations. Over 600 AI 
community members have now participated in these educational 
events with pre and post-testing demonstrating improved knowl-
edge. If interested, these participants are referred to our cancer 
screening coordinators (CSCs) who work within the IHS clinic/
hospital on each reservation and in Rapid City to arrange for cancer 
screening (Figure 2). If patients are diagnosed with cancer, they are 
eventually referred to the cancer navigators in Rapid City who are 
part of the cancer team. To date, 272 AIs have undergone cancer 
screening as a result of these educational workshops. In addition, 
our community navigation program coordinates cancer screening 
events by networking with other organizations such as the Susan 
FIguRe 2 | Walking forward comprehensive patient navigation 
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BUILDINg FROM SUCCESS
Some of the lessons learned were predictable, the experience was 
challenging yet invigorating and a number of the observations 
are profound. It was predictable that distance from the treatment 
center, transportation, family and work obligations, and financial 
considerations adversely impacted cancer care. That the stage at 
diagnosis was advanced was expected but that there was such a 
paucity of clinical trials within the NCI portfolio was an excellent 
lesson learned. Indeed, some of the treatment regimens tailored to 
advanced disease and limited duration of therapy for CDRP are 
applicable worldwide for disparities populations. That it would 
require effort to build trust was expected, but the desire on the 
part of the community and AIs to indeed build trust was very 
strong. The supposition by some that AIs would never agree to 
tissue biomarker studies was wrong. That people would readily 
cross a range of barriers to fight the common enemy of disease 
was uplifting and the spread of AI self-advocacy from cancer care 
to other aspects of health care as a result of CDRP and WF is a 
terrific spinoff. The struggle to sustain the program was an issue 
and remains a serious challenge. Appropriately, some program 
reviewers said “we were taking on the toughest challenges.” We 
agreed and argue that if you can solve the toughest ones, you 
can simultaneously solve many easier ones. This program was 
granted a final 5-year period in 2009 so new sources of support 
will be needed.
Perhaps the most profound lesson is the importance of effort, 
caring, listening, and learning from one another and the good that 
comes to both sides of the provider-patient equation. The progress 
made by WF and all of those involved emphasizes how much a 
small number of dedicated individuals who are trying to make a 
difference can really make.
“Never doubt that a small group of thoughtful, committed citi-
zens can change the world; indeed, it’s the only thing that ever does” 
Margaret Mead (http://thinkexist.com/quotation/never_doubt_
that_a_small_group_of_thoughtful/199313.html).
A key lesson learned is the value of person-to-person relation-
ships and how such trust, caring, and effort can be effective. Sadly, 
there are few opportunities for this community/altruistic type of 
work within a medical career, a gap we hope to fill with a new con-
cept the Medical Expert Corps and Cancer Expert Corps: The Peace 
Corps for Cancer to address health disparities for chronic diseases. 
That is a work in progress and the success of WF demonstrates the 
multiplier effect of such efforts (Reynolds, 2010).
CONCLUSION
Walking Forward is a community-based program that has achieved 
several measures of success including establishment of trust within 
the AI population, unprecedented rates of clinical trial accrual, and 
creation of a research infrastructure that permits us to address 
ongoing research questions of relevance to this community. 
Through a comprehensive patient navigation program a reduction 
in cancer mortality is anticipated as AIs will present with earlier 
stages of cancer, and therefore, will have increase eligibility for 
access to clinical trials.
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  intermediate-, and high-risk prostate cancer (non-metastatic). 
A central theme to these studies was the use of hypofractionation 
to exploit a potential radiobiologic advantage and to decrease 
the overall treatment time. The low-risk prostate study was one 
of the most successful trials opened in Rapid City as we accrued 
nearly 50 patients and the trial met the needs of our population. 
Nationally, this trial has accrued over 300 patients with excellent 
biochemical control rates, but with late G2 rectal bleeding rates 
of 8% which have all resolved. Implications for this are discussed 
below in the ATM section.
There is currently a need in the US to offer patients participa-
tion in clinical trials that address both special needs and a relevant, 
oncologic issue. For example, women in our part of the country 
had a low accrual rate to the phase III NSABP B-39 /RTOG 0413 
trial (n = 4); whereas, women were eager to participate in our 
phase II breast brachytherapy trial (n = 47). Many of these women 
trial indicated they would choose a mastectomy over 6 weeks of 
external beam radiotherapy due to the distance from the cancer 
center. Thus, the needs of these special populations should be 
considered among the cooperative groups in the design of future 
phase II, clinical trials for institutions that serve these populations. 
Themes worthy of investigation include hypofractionation, dose 
escalation, radiosensitizers, minimization of toxicities and resource 
sparing. Hypofractionation currently remains investigational, but 
if validated by ongoing trials, the potential exists for a significant 
therapeutic gain, as well as substantial health care cost and utiliza-
tion advantages. These trials will have significant implications for 
radiation delivery in resource limited countries.
RADIOgENOMICS
As part of the original research design, the ATM gene was inves-
tigated as there was concern that the AI patient population was 
more sensitive to the effects of therapeutic radiation. Fear of this 
treatment related side effect could potentially contribute to the 
commonly observed treatment delays observed in this patient pop-
ulation. To date, 100 AI and 100 non-AI participated in the ATM 
study (Petereit and Burhansstipanov, 2008; Petereit et al., 2010). 
This study provided new information on the ethnic distribution 
of ATM SNPs in a regional US population, and was the first to 
determine the prevalence of ATM SNPs in AIs. Correlating the SNP 
data with available patient toxicity data is underway and may reveal 
any important SNPs that can be predictive of radiosensitivity. There 
is no support in our study for the hypothesis that a difference in 
prevalence or type of ATM SNPs explains the different spectrum 
of side-effects seen after radiotherapy in AI versus non-AI patients.
As an extension of the ATM study, we are investigating the 
genetic risk profiles of individuals by identifying genes through 
DNA microarrays that might predict response to treatment, and 
ultimately, guide therapy. The ultimate goal is to identify markers 
that could be used to identify patients that might have an adverse 
response prior to treatment and to determine whether the causes of 
susceptibility of AI and other populations are similar or different. 
This is particularly relevant in our population as data continues 
to mature that supports the role of hypofractionation in a number 
of clinical scenarios; however, if patients exhibited a molecular 
profile of increased radiosensitivity, than these strategies would 
not be contraindicated.Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 11  |  8
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